Canvas Dx
Overview
Cognoa is a pediatric behavioral health company that develops digital diagnostic and therapeutic products for children with behavioral health disorders.5 to 6 years. The tool leverages responsible artificial intelligence to provide an informed, rapid, and universally accessible path to care, aiming to overcome diagnostic delays and inequities. Canvas Dx utilizes a combination of caregiver questionnaires, home video recordings of the child’s behavior, and clinician input, processed by a machine-learning algorithm, to aid in diagnosis.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered diagnostic aid for autism
- Diagnoses or rules out autism in children ages 1.5 to 6 years
- Remote, digital evaluation via smartphone app for caregivers
- Caregiver questionnaires and home video recordings
- Clinician questionnaire and portal
- Machine-learning algorithm processes independent inputs
- Provides positive, negative, or indeterminate diagnosis for ASD
- Auto-generates detailed developmental reports
- Supports rapid diagnosis (days, not months or years)
- Objective, data-driven approach to alleviate biases
Use Cases
- Early diagnosis of Autism Spectrum Disorder (ASD) in young children
- Reducing diagnostic delays for autism
- Equipping primary care clinicians to diagnose autism
- Overcoming geographical barriers to specialized care
- Providing objective, data-driven insights to aid clinical judgment
- Streamlining the path to care and intervention
What Physicians Need to Know
Canvas Dx is a prescription-only diagnostic aid for autism in children aged 18-72 months. It is not a standalone diagnostic tool and should be used in conjunction with your clinical expertise and other evidence. Utilize the detailed reports provided by Canvas Dx, which map concerns to DSM-5 criteria, to inform your diagnostic decisions and guide next steps for every child, regardless of the Canvas Dx outcome. For indeterminate results, further specialist evaluation is typically warranted. The tool aims to expedite diagnosis, potentially allowing for earlier interventions, which are critical for improving long-term outcomes.
Details
| Category | Clinical Decision Support & Reference, Mental & Behavioral Health AI |
| Pricing | Unknown |
| Deployment | Remote, digital evaluation |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Family Medicine, Pediatrics, Psychiatry |
FDA clearance history
This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.
| Decision date | Number | Name as listed by FDA |
| 2025-04-11 | K243558 510(k) | Canvas Dx |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Canvas Dx
Videos
Product demos, reviews, and walkthroughs for Canvas Dx.
AI in Action E286: Dennis Wall, Founder at Cognoa
Alldus International



